Open this publication in new window or tab >>Show others...
2023 (English)In: Nature, ISSN 0028-0836, E-ISSN 1476-4687, Vol. 620, no 7973, p. 381-385Article in journal (Refereed) Published
Abstract [en]
The human gut microbiota has gained interest as an environmental factor that may contribute to health or disease. The development of next-generation probiotics is a promising strategy to modulate the gut microbiota and improve human health; however, several key candidate next-generation probiotics are strictly anaerobic and may require synergy with other bacteria for optimal growth. Faecalibacterium prausnitzii is a highly prevalent and abundant human gut bacterium associated with human health, but it has not yet been developed into probiotic formulations. Here we describe the co-isolation of F. prausnitzii and Desulfovibrio piger, a sulfate-reducing bacterium, and their cross-feeding for growth and butyrate production. To produce a next-generation probiotic formulation, we adapted F. prausnitzii to tolerate oxygen exposure, and, in proof-of-concept studies, we demonstrate that the symbiotic product is tolerated by mice and humans (ClinicalTrials.gov identifier: NCT03728868) and is detected in the human gut in a subset of study participants. Our study describes a technology for the production of next-generation probiotics based on the adaptation of strictly anaerobic bacteria to tolerate oxygen exposures without a reduction in potential beneficial properties. Our technology may be used for the development of other strictly anaerobic strains as next-generation probiotics.
Place, publisher, year, edition, pages
Springer Nature, 2023
National Category
Microbiology
Identifiers
urn:nbn:se:umu:diva-230774 (URN)10.1038/s41586-023-06378-w (DOI)001045155200013 ()37532933 (PubMedID)2-s2.0-85166553228 (Scopus ID)
Funder
Swedish National Infrastructure for Computing (SNIC), SNIC 2020/5-384Swedish National Infrastructure for Computing (SNIC), SNIC 2019/8-169Knut and Alice Wallenberg Foundation, 2017.0026Swedish Research Council, 2019-01599Swedish Research Council, 2018-05973Swedish Heart Lung Foundation, 20210366Novo Nordisk Foundation, NNF17OC0028232Region Västra Götaland, ALFGBG-718101AFA Insurance
2024-10-102024-10-102024-10-10Bibliographically approved